Abstract
Oxidative stress is implicated in the pathogenesis of neurodegenerative diseases, including sporadic Alzheimer´s disease (AD). Mitochondrial DNA (mtDNA) deletions are markers of oxidative damage and increase with age. To unravel the impact of mtDNA damage on AD development, we analyzed mtDNA deletion levels in diverse neuronal cell types of four brain regions (hippocampal CA1 and CA2 regions, nucleus tractus spinalis nervi trigemini, and the cerebellum) that exhibit differing levels of vulnerability to AD related changes at progressive Braak stages compared with age-matched controls. Neurons from these four brain regions were collected using laser microdissection, and analyzed using quantitative polymerase chain reaction (qPCR). Although, no correlation between mtDNA deletion levels and AD progression were found, the data revealed regional and cell type specific selective vulnerability towards mtDNA deletion levels. In conclusion, unexpected results were obtained as granule cells from the cerebellum and neurons from the nucleus tractus spinalis nervi trigemini of the brain stem displayed significant higher mtDNA deletion levels than pyramidal cells from hippocampal CA1 and CA2 region in age and AD.
Keywords: Alzheimer´s disease, deletion, neurodegeneration, neuronal mitochondrial DNA, oxidative stress, selective vulnerability.
Current Alzheimer Research
Title:Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
Volume: 10 Issue: 10
Author(s): Anne Gerschütz, Helmut Heinsen, Edna Grünblatt, Anne K. Wagner, Jasmin Bartl, Christoph Meissner, Andreas J. Fallgatter, Safa Al-Sarraj, Claire Troakes, Isidro Ferrer, Thomas Arzberger, Jürgen. Deckert, Peter Riederer, Matthias Fischer, Thomas Tatschner and Camelia M. Monoranu
Affiliation:
Keywords: Alzheimer´s disease, deletion, neurodegeneration, neuronal mitochondrial DNA, oxidative stress, selective vulnerability.
Abstract: Oxidative stress is implicated in the pathogenesis of neurodegenerative diseases, including sporadic Alzheimer´s disease (AD). Mitochondrial DNA (mtDNA) deletions are markers of oxidative damage and increase with age. To unravel the impact of mtDNA damage on AD development, we analyzed mtDNA deletion levels in diverse neuronal cell types of four brain regions (hippocampal CA1 and CA2 regions, nucleus tractus spinalis nervi trigemini, and the cerebellum) that exhibit differing levels of vulnerability to AD related changes at progressive Braak stages compared with age-matched controls. Neurons from these four brain regions were collected using laser microdissection, and analyzed using quantitative polymerase chain reaction (qPCR). Although, no correlation between mtDNA deletion levels and AD progression were found, the data revealed regional and cell type specific selective vulnerability towards mtDNA deletion levels. In conclusion, unexpected results were obtained as granule cells from the cerebellum and neurons from the nucleus tractus spinalis nervi trigemini of the brain stem displayed significant higher mtDNA deletion levels than pyramidal cells from hippocampal CA1 and CA2 region in age and AD.
Export Options
About this article
Cite this article as:
Gerschütz Anne, Heinsen Helmut, Grünblatt Edna, Wagner K. Anne, Bartl Jasmin, Meissner Christoph, Fallgatter J. Andreas, Al-Sarraj Safa, Troakes Claire, Ferrer Isidro, Arzberger Thomas, Deckert Jürgen., Riederer Peter, Fischer Matthias, Tatschner Thomas and Monoranu M. Camelia, Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease, Current Alzheimer Research 2013; 10 (10) . https://dx.doi.org/10.2174/15672050113106660166
DOI https://dx.doi.org/10.2174/15672050113106660166 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Intravenous Anesthetics: A New Critical Perspective
Current Pharmaceutical Design An Overview of Phenserine Tartrate, A Novel Acetylcholinesterase Inhibitor for the Treatment of Alzheimers Disease
Current Alzheimer Research Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Resurrecting Clinical Pharmacology As a Context for Alzheimer Disease Drug Development
Current Alzheimer Research Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Reviews on Recent Clinical Trials Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets CSF as a Surrogate for Assessing CNS Exposure: An Industrial Perspective
Current Drug Metabolism Persistent Psychosis from Toluene Exposure; More Likely Coincidence than Cause: A Review of our Experience and the Literature
Current Psychiatry Reviews Editorial (Thematic Issue: Molecular Imaging in Dementia: From the State of the Art to the New Perspectives)
Current Alzheimer Research Protective Substances Against Zinc-Induced Neuronal Death after Ischemia:Carnosine as a Target for Drug of Vascular Type of Dementia
Recent Patents on CNS Drug Discovery (Discontinued) Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities
Current Pharmaceutical Biotechnology Increased Acetylation of Histone H4 at Lysine 12 (H4K12) in Monocytes of Transgenic Alzheimer’s Mice and in Human Patients
Current Alzheimer Research Pleiotropic Effects of the Rho-kinase Inhibitor Fasudil After Subarachnoid Hemorrhage: A Review of Preclinical and Clinical Studies
Current Vascular Pharmacology The Role of ER Stress-Induced Apoptosis in Neurodegeneration
Current Alzheimer Research Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Is There Any Scientific Basis of Hawan to be Used in the Alzheimer’s Disease Prevention/Cure?
Current Traditional Medicine